Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results

November 21, 2011

SHENZHEN, China, Nov. 21, 2011 /PR Newswire-Asia/ – Global Pharm Holdings Group, Inc. (OTCBB: GPHG) (“Global Pharm” or the “Company”), a growing vertically integrated pharmaceutical company engaged in the distribution of pharmaceutical-related products, Traditional Chinese Medicine (“TCM”) processing, and herbal cultivation and sales in China through its subsidiaries in Anhui, Jilin, Guangdong and Shandong provinces, today announced its unaudited financial results for the third quarter ended September 30, 2011.

Third Quarter 2011 Highlights

  • Net revenues were $69.0 million, an increase of 125.4% as compared to the third quarter of 2010.
  • Gross profit was $9.6 million, an increase of 62.1% as compared to the third quarter of 2010, with gross margin of 13.9%.
  • Operating income was $6.1 million, an increase of 449.8% as compared to the third quarter of 2010.
  • Net income was $3.7 million, or $0.12 per diluted share, as compared to net loss of $0.07 million, or nil per diluted share, for the same period in 2010.
  • In July 2011, Global Pharm successfully acquired a TCM herbal pieces processing plant in Bozhou, Anhui Province.
  • In August 2011, Global Pharm successfully acquired a city-level pharmaceutical distributor in Weifang, Shandong Province. Furthermore, through its acquisition in August 2011 of the management and supply distribution rights to one of the largest pharmaceutical franchise of drugstores in Guangdong Province, the Company currently manages over 1,200 retail and chain drugstores in the area.
  • In September and October 2011, the Company issued redeemable convertible bonds in the aggregate principal amount of $15,000,000 to Blazer Delight Limited, an investment vehicle owned by a fund managed by Asia-based Gen2 Partners Limited.

“We’re pleased to report a successful quarter marked by strong financial performance and important operational achievements. During the third quarter of 2011, we have further expanded our distribution network coverage in Shandong Province and Guangdong Province through new acquisitions, and completed the $15,000,000 convertible bonds financing, the proceeds of which will be used for our future growth,” stated Mr. Yunlu Yin, Chief Executive Officer of Global Pharm.


           Third Quarter 2011 Financial Summaries (unaudited)
                                             Three months ended September 30
    (in millions $, except per-share
    data in $)                              2011       2010     % Change
    Net Revenue                             $69.0      $30.6       125.4%
    Gross Profit                              9.6        5.9        62.1%
    Income from operation                     6.1        1.1       449.8%
    Income before income taxes                5.3        1.1       378.4%
    Net Income (loss)                         3.7      (0.07)          -
    Total comprehensive income                3.4       (0.2)          -
    Diluted earnings per share               0.12          -         N/A

Total net revenue was $69.0 million for the three months ended September 30, 2011, an increase of 125.4%, as compared with the same period in 2010. The increase was primarily due to the additional revenue contributed by the distribution business of our newly-acquired subsidiaries in 2011, amounting to $23.6 million, and the increased sales of $11.9 million by Shandong Global Pharm Group, Ltd. (“Shandong Global”).

Below is a breakdown of sales per business segment for the three months ended September 30, 2011 and 2010, respectively:


                        For the three months ended September 30 - Revenue (unaudited)
                        -------------------------------------------------------------
              in US $
               except
             percentage                        2011                           2010            Change
             ----------                        ----                           ----            ------
                                         % of revenue                  % of revenue                    %
     Pharmaceutical
     products
     distribution         $62,651,819          90.8    $24,810,775            81.0    $37,841,044    152.5
    TCM
     processing
     and
     distribution           5,564,765           8.1      4,465,935            14.6      1,098,830     24.6
    Herbal
     cultivation
     and sales                782,509           1.1      1,341,110             4.4       (558,601)   (41.7)
                              -------           ---      ---------             ---       --------    -----
    Total                 $68,999,093         100.0    $30,617,820           100.0    $38,381,273    125.4
                          ===========         =====    ===========           =====    ===========    =====

Revenue from the pharmaceutical products distribution segment increased by $37.8 million, or approximately 152.5%, to $62.7 million for the three months ended September 30, 2011, as compared to $24.8 million for the same period in 2010. The increase was primarily due to the additional revenue contribution from our four newly-acquired distribution subsidiaries in 2011. Revenue from the Company’s TCM processing and distribution segment increased to $5.6 million for the third quarter of 2011, as compared to $4.5 million for the comparable period in 2010. The increase is mainly due to $2.5 million in additional revenue from our newly-acquired subsidiary, Bozhou Xinghe Pharmaceutical Co., Ltd. (“Bozhou Xinghe”), offset by an approximately $1.0 million decrease in the revenue of our other subsidiary, Anhui Xuelingxian Pharmaceutical Co., Ltd. (“Xuelingxian”). Our flower tea bags operations have been suspended since April 25, 2011, as such, we had nil revenue from this business, as compared to sales of $0.8 million for the three months ended September 30, 2010. Revenue from our herbal cultivation and sales segment was $0.8 million for the three months ended September 30, 2011, a decrease of approximately $0.6 million, or 41.7%, as compared to $1.3 million for the same period in 2010. The decrease was mainly due to reduced sales by Xuelingxian for three months ended September 30, 2011, because our herbal products were harvested in late September 2011 and sold after September 30, 2011, as compared to our earlier harvest of herbal products for the comparable period in 2010, of which some sales were recorded in the same quarter.

Gross profit for the third quarter of 2011 was $9.6 million, an increase of 62.1%, from $5.9 million for the comparable period in 2010. Gross margin decreased to 13.9% for the third quarter of 2011 from 19.3%, for the comparable period in 2010, primarily attributable to the lower gross profit margin of our four newly-acquired subsidiaries, which had an average gross profit margin of 6.47%.

Operating expenses for the third quarter of 2011 were $1.1 million, an increase of $0.7 million, as compared to the same period in 2010, primarily due to the additional operating expenses attributed to our newly-acquired subsidiaries in 2011, as well as to the increased advertising, freight and labor costs to support our business growth and expansion.

Income from operation for the third quarter of 2011 increased 449.8% to $6.1 million, or 8.8% of total revenue, from $1.1 million, or 3.6% of total revenue for the comparable period in 2010.

Net income for the third quarter of 2011 increased to $3.7 million, or $0.12 per fully diluted share, compared to a net loss of $72,376 for the same period in 2010, based on 28.9 million and 26.0 million weighted average diluted shares outstanding, respectively. This increase was primarily due to the one-time expense of the $3.0 million in stock-based compensation, which was recorded as general and administrative expenses in the three months period ended September 30, 2010, and had a significant impact on our net income.


         Nine Months 2011 Financial Summaries (unaudited)
                                            Nine months ended September 30
    (in millions $, except per-share data in $)      2011    2010    % Change
    Net Revenue                                     $156.2   $90.2     73.2%
    Gross Profit                                      24.8    16.6     49.6%
    Income from operation                             18.2     9.3     95.5%
    Income before income taxes                        17.4     9.3     86.3%
    Net Income                                        12.9     5.7    126.0%
    Total comprehensive income                        12.5     5.6    124.4%
    Diluted earnings per share                        0.47    0.22    113.6%

Total net revenue was $156.2 million for the nine months ended September 30, 2011, an increase of 73.2%, as compared to the same period in 2010. The increase was primarily due to the additional revenue contributed by our newly-acquired subsidiaries in 2011, amounting to $25.1 million, and the increased sales of $35.2 million and $6.0 million by our subsidiaries, Shandong Global Tonghua Tongdetang Pharmaceutical and Medicinal Material Co., Ltd. (“Tongdetang”), respectively.

Below is a breakdown of our sales by business segment for the nine months ended September 30, 2011 and 2010, respectively:


                       For the nine months ended September 30 - Revenue (unaudited)
                       ------------------------------------------------------------
             in US $
              except
            percentage                             2011                       2010          Change
            ----------                             ----                       ----          ------
                                            % of revenue                % of revenue                  %
     Pharmaceutical
     products
     distribution          $134,481,832            86.1  $68,183,762          75.6   $66,298,070    97.2
    TCM
     processing
     and
     distribution            16,238,510            10.4   20,646,774          22.9    (4,408,264)  (21.4)
    Herbal
     cultivation
     and
     sales                    5,447,635             3.5    1,345,969           1.5     4,101,666   304.7
                              ---------             ---    ---------           ---     ---------   -----
    Total                  $156,167,977           100.0  $90,176,505         100.0   $65,991,472    73.2
                           ============           =====  ===========         =====   ===========    ====

Revenue from the pharmaceutical products distribution segment increased by $66.3 million, or approximately 97.2%, to $134.5 million for the nine months ended September 30, 2011, as compared to $68.2 million for the same period in 2010. The increase was primarily due to the additional revenue contributed by our four newly-acquired subsidiaries in 2011, and the increased sales by Shandong Global and Tongdetang. Revenue from our TCM processing and distribution segment decreased to $16.2 million for the nine months ended September 30, 2011, as compared to $20.6 million for the comparable period in 2010. The decrease is mainly due to the decrease in Xuelingxian’s revenue from its TCM processing and distribution operations, amounting to $3.2 million, offset against the $2.5 million in additional revenue from Bozhou Xinghe. Our flower tea bags operations have been suspended since April 25, 2011, as such, we had nil revenue from this business, as compared to sales of $3.7 million for the nine months ended September 30, 2010. Revenue from our herbal cultivation and sales segment was $5.4 million for the nine months ended September 30, 2011, as compared to $1.3 million for the comparable period in 2010, an increase of approximately $4.1 million, or 304.7%. The increase was mainly due to sales of our entire remaining inventory of herbal products harvested during 2010 in the first quarter of 2011, amounting to $4.7 million.

Gross profit for nine months ended September 30, 2011 was $24.8 million, an increase of 49.6%, from $16.6 million for the same period in 2010. Gross margin decreased to 15.9% for the nine months ended September 30, 2011, from 18.4% for the comparable period in 2010. The decrease is primarily attributable to the lower gross profit margin of our newly-acquired subsidiaries, which had an average gross profit margin of 5.9%.

Operating expenses for the nine months ended September 30, 2011 were $2.4 million, an increase of $1.7 million, as compared to the same period in 2010, primarily due to the additional operating expenses attributed to our newly-acquired subsidiaries in 2011.

Income from operation for the nine months ended September 30, 2011 increased 95.5% to $18.2 million, or 11.6% of total revenue, from $9.3 million, or 10.3% of total revenue for the third quarter of 2010.

Net income for the nine months ended September 30, 2011 increased to $12.9 million, or $0.47 per fully diluted share, as compared to $5.7 million, or $0.22 per fully diluted share, for the same period of 2010, based on 27.0 million and 26.0 million weighted average diluted shares outstanding, respectively.

Financial Condition

As of September 30, 2011, the Company had $18.6 million in cash and $34.1 million in accounts receivable, as compared to $4.3 million and $19.8 million as of December 31, 2010, respectively. The increase was consistent with the increase in sales. The net working capital was $31.9 million, as compared to $17.4 million as of December 31, 2010. As of September 30, 2011, the Company had $5.0 million in short-term debt, as compared to $2.0 million as of December 31, 2010. Shareholders’ equity totaled $76.4 million as of September 30, 2011, as compared to $17.6 million as of the end of 2010.

For the nine months ended September 30, 2011, the Company generated $6.0 million cash from operating activities, as compared to $3.2 million for the comparable period in 2010. The net income for the nine months ended September 30, 2011 was $12.9 million, an increase of $7.2 million from $5.7 million for the comparable period in 2010. In addition to net income, the cash generated from operating activities was the net effect of the increase in accounts receivables of approximately $6.2 million, the increase in inventories of $7.4 million, the increase of restricted cash and other current assets of $5.1 million, the increase in accounts payable and accruals of $5.1 million, and the increase in amounts due to related parties of $5.3 million. The Company used $1.0 million in investing activities for the nine months ended September 30, 2011, as compared to $0.02 million for the comparable period in 2010, primarily as a result of increased expenditures relating to acquisitions of new businesses and equipment. Net cash provided by financing activities was $9.0 million for the nine months ended September 30, 2011, as compared to $2.9 million used for the comparable period in 2010. The cash provided in financing activities for the nine months ended September 30, 2011 was due to our repayment of loans of $2.6 million and the proceeds received from our convertible bonds financing of $10.0 million.

Subsequent Events

On October 20, 2011, the Company issued an additional redeemable convertible bond in the aggregate principal amount of $5,000,000 to Blazer Delight Limited, under the terms of the Subscription Agreement dated September 19, 2011, which the Company entered into with Mr. Yunlu Yin and Blazer Delight Limited, and the relevant Bond Instrument.

On October 31, 2011, the Company completed the acquisition of the 100% equity interest of Qingdao Likang Pharmaceutical Co., Ltd, a city-level pharmaceutical distributor located in Qingdao, Shandong Province.

Business Outlook

Global Pharm will continue to selectively acquire more distributors which can complement our business. For the rest of 2011, the Company is focusing on the quality of its operations through undertaking measures to enhance its unified management systems, such as improving the integrated information, procurement and sales-team management systems, in order to leverage the resources of each business segment and create synergies across all of them.

About Global Pharm

Global Pharm Holdings Group, Inc., a growing integrated pharmaceutical company, is engaged in the distribution of pharmaceutical-related products, Traditional Chinese Medicine (TCM) processing, and herbal cultivation and sales in China. The Company focuses on building regional distribution channels, as well as local capillary sales network with a high-margin product portfolio. Currently, its sales network covers Shandong, Jilin, Anhui and Guangdong provinces. Global Pharm seeks to establish an integrated value chain in the pharmaceutical industry through strategic acquisitions within the TCM production, pharmaceutical distribution and retail sectors. For further information, please visit the Company’s corporate website at http://www.globalpharmholdings.com.

Forward-looking Statements

Certain statements set forth in this press release contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, our management as well as estimates and assumptions made by our management. Such statements reflect the current view of our management with respect to future events and are subject to risks, uncertainties, assumptions and other factors as they relate to our industry, our operations and results of operations, plans for future facilities, capital-expenditure plans and any businesses that we may acquire. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the U.S. federal securities laws, we do not intend to update any of the forward-looking statements to conform them to actual results.

For Additional Information Contact

Global Pharm Holdings Group, Inc.
Ms. Susan Liu
Phone: +86-755-3693-9373
Email: susanliu@globalpharmholdings.com

-FINANCIAL TABLES FOLLOW–


                            GLOBAL PHARM HOLDINGS GROUP, INC
                          CONDENSED CONSOLIDATED BALANCE SHEETS

                                                  September 30, December 31,
                                                           2011         2010
                                                    (unaudited)
    ASSETS
    Current assets:
      Cash and cash equivalents                     $18,570,246   $4,271,498
      Accounts receivable                            34,069,776   19,771,619
      Inventories                                    29,852,272   16,058,760
      Due from related party                            194,708            -
      Restricted cash                                 3,781,418    1,538,251
      Other current assets                            5,355,851    1,326,660
                                                      ---------    ---------
       Total current assets                          91,824,271   42,966,788
    Property, plant and equipment, net                8,505,797      210,665
    Intangible assets, net                           33,860,597            -
    Goodwill                                         27,043,851            -
                                                     ----------          ---
        Total assets                               $161,234,516  $43,177,453
                                                   ============  ===========

    LIABILITIES AND SHAREHOLDERS' EQUITY
    Current liabilities:
      Short-term loan                                $5,003,753   $1,972,150
      Bank acceptance                                 4,805,339       21,212
      Accounts payable and other accrued
       liabilities                                   39,900,624   20,944,923
      Income and other taxes payable                  2,959,555    1,728,499
      Due to related party                            6,729,332      882,505
      Deferred income tax liabilities                   491,360            -
                                                        -------          ---
       Total current liabilities                     59,889,963   25,549,289
    Long-term loan                                    1,563,673            -
    Bond payable, net                                 4,436,318            -
    Derivative liabilities                            5,563,682            -
    Contingent consideration, at fair value           5,765,708            -
    Deferred income tax liabilities, net of
     current                                          7,653,272            -
       Total liabilities                             84,872,616   25,549,289
                                                     ----------   ----------

    Shareholder's equity:
      Common stock, par value, $0.001 per
       share, 100,000,000 shares                         37,283       26,000
      authorized, 37,283,185 and 26,000,000 issued and
       outstanding
      Additional paid-in capital                     55,089,340    9,200,623
      Statutory surplus reserves                      1,310,701    1,310,701
      Retained earnings                              19,445,014    6,546,406
      Accumulated other comprehensive income            137,618      544,434
                                                        -------      -------
       Total shareholders' equity -Global Pharm
        Holdings Group, Inc.                         76,019,956   17,628,164
       Non-controlling interests                        341,944            -
                                                        -------          ---
        Total shareholders' equity                   76,361,900   17,628,164
                                                     ----------   ----------
        Total liabilities and shareholders'
         equity                                    $161,234,516  $43,177,453
                                                   ============  ===========


                       CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
                                                    (unaudited)
                                                   Three months ended              Nine months ended September
                                                     September 30,                             30,
                                                     2011           2010                  2011          2010
                                                     ----           ----                  ----          ----
    Revenues, net                             $68,999,093    $30,617,820          $156,167,977   $90,176,505
    Cost of goods sold                         59,427,311     24,711,477           131,405,558    73,622,656
                                               ----------     ----------           -----------    ----------
    Gross profit                                9,571,782      5,906,343            24,762,419    16,553,849
    Expenses:
        Operating expenses                      1,100,309        360,572             2,447,617       725,424
        General and
         administrative                         2,370,710      4,436,082             4,136,902     6,531,617
                                                ---------      ---------             ---------     ---------
    Income from operations                      6,100,763      1,109,689            18,177,900     9,296,808
    Other income and
     expenses
    Interest (expense)
     income                                       (99,087)         2,842              (101,100)       21,048
    Miscellaneous (expense)
     income                                       (13,511)             -               (48,110)           -
      Change in fair value of
       contingent
       consideration                             (665,708)             -              (665,708)           -
                                                 --------            ---              --------          ---
    Income before income
     taxes                                      5,322,457      1,112,531            17,362,982     9,317,856
    Provision for income
     taxes                                      1,589,240      1,184,907             4,468,365     3,609,764
                                                ---------      ---------             ---------     ---------
    Net income (loss) -
     including non-
     controlling interest                       3,733,217        (72,376)           12,894,617     5,708,092
    Net loss - non-
     controlling interests                          2,664              -                 3,991            -
                                                    -----            ---                 -----          ---
    Net income (loss) -
     Global Pharm Holdings
     Group, Inc.                                3,735,881        (72,376)           12,898,608     5,708,092
    Other comprehensive
     income
    Foreign currency
     translation adjustment                      (351,777)      (174,718)             (406,816)     (142,492)
                                                 --------       --------              --------      --------
    Total comprehensive
     income (loss)                             $3,384,104      ($247,094)          $12,491,792    $5,565,600
                                               ==========      =========           ===========    ==========
    Earnings per share of
     common stock:
    Basic earnings per
     share                                          $0.13             $-                 $0.48         $0.22
                                                    -----            ---                 -----         -----
    Diluted earnings per
     share                                          $0.12             $-                 $0.47         $0.22
                                                    -----            ---                 -----         -----
    Weighted-average
     outstanding common
     shares
      Basic weighted-average
       outstanding common
       shares                                  28,727,803     26,000,000            26,909,268    26,000,000
      Diluted weighted-
       average outstanding
       common shares                           28,947,583     26,000,000            26,982,528    26,000,000


                             GLOBAL PHARM HOLDINGS GROUP, INC
                     CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                       (unaudited)
                                                              Nine Months Ended
                                                                September 30,
                                                                2011               2010
    Cash flows from operating activities
    Net income-including non-
     controlling interest                                $12,894,617         $5,708,092
    Adjustments to reconcile net income to net cash
     provided by operating activities:
    Depreciation and amortization                            672,729             51,993
    Merger cost                                                    -            750,000
    Stock-based compensation                                       -          4,476,300
    Change in fair value of contingent
     consideration                                           665,708                  -
    Changes in operating assets and liabilities:
    Accounts receivable                                   (6,236,658)        (4,683,793)
    Inventories                                           (7,390,787)       (14,211,786)
    Due from related party                                   (29,576)                 -
    Restricted cash                                       (2,161,403)                 -
    Other current assets                                  (2,968,622)          (199,796)
    Accounts payable and other accrued
     liabilities                                           5,139,874         11,014,731
    Income and other taxes payable                           183,235            294,485
    Due to related party                                   5,348,883                  -
    Deferred tax expenses                                    (85,477)                 -
                                                             -------                ---
    Net cash provided by operating
     activities                                            6,032,523          3,200,226

    Cash flows from investing activities
    Purchase of property, plant and
     equipment                                              (432,647)           (22,044)
    Proceeds on sale of assets                                41,606                  -
    Acquisition of subsidiaries, net
     of cash acquired                                       (555,305)                 -
                                                            --------                ---
    Net cash used in investing
     activities                                             (946,346)           (22,044)

    Cash flows from financing activities:
    Short-term loan borrowing                                      -            366,763
    Short-term loan repayments                            (2,616,506)                 -
    Bank acceptance                                        1,308,357           (199,545)
    Due from related party                                         -             24,603
    Due to related party                                           -          1,168,986
    Dividend paid to the former
     shareholders                                                  -         (4,309,377)
    Cash received from convertible
     bond                                                 10,000,000                  -
    Contribution from non-controlling
     interest                                                344,835                  -
                                                             -------                ---
    Net cash provided by (used in)
     financing activities                                  9,036,686         (2,948,570)

    Net increase in cash and cash
     equivalents                                          14,122,863            229,612
    Effect of exchange rate changes on
     cash and cash equivalents                               175,885            145,532
    Cash and cash equivalents -
     beginning of period                                   4,271,498          7,455,147
                                                           ---------          ---------
    Cash and cash equivalents -end of
     period                                              $18,570,246         $7,830,291
                                                         ===========         ==========

    Supplemental disclosure of cash flow
     information:
    Cash paid for interest                                  $148,866            $20,655
    Cash paid for income taxes                            $3,927,576         $2,994,851

    Supplemental disclosure of financing activities
    Deferred Bond issuance costs in
     accounts payable                                       $287,500                 $-
    Common stock issued for
     acquisitions                                        $51,000,000                 $-

SOURCE Global Pharm Holdings Group, Inc.


Source: PR Newswire